Anticancer Therapies – Products

AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.

Active cell therapy drugs represent the latest in cancer treatment. Of these, chimeric antigen receptor (CAR) cell modalities are considered the most successful.

CAR-T cell therapy has emerged as one of the most promising novel treatments in the fight against cancer.

Certis Oncology Solutions has announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

Cantargia has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab, in pancreatic cancer patients.

CureSearch for Children’s Cancer has announced that it will fund a Phase I clinical trial to bring new therapies to pediatric brain cancer patients, including those with limited or no treatment options.

EpicentRx, Inc. has announced that the FDA has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head & neck cancer patients.

Thermo Fisher Scientific and Arsenal Biosciences, Inc. have announced an update to their strategic collaboration to further the development of manufacturing processes for new cancer treatments.

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.

Metabolism is a key driver of CAR-T cell fitness and function. Hence, metabolic preconditioning methods can enhance the bioenergetic capacity of CAR-T cells in culture, supporting their persistence and antitumor activity